Daily Archives: February 14, 2020
Towards genetic prediction of non-alcoholic fatty liver disease trajectories: PNPLA3 and beyond
Non-alcoholic fatty liver disease (NAFLD) is on the verge of becoming the leading cause of liver disease. NAFLD develops at the interface between environmental factors and inherited predisposition. Genome-wide association studies, followed by exome-wid… Continue reading
Posted in News
Comments Off on Towards genetic prediction of non-alcoholic fatty liver disease trajectories: PNPLA3 and beyond
The cell circuitry of ulcerative colitis, a new view for a highly complex disease.
Posted in News
Comments Off on The cell circuitry of ulcerative colitis, a new view for a highly complex disease.
Metabolic inflammation – a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)?
Non-alcoholic fatty liver disease (NAFLD) is a global and growing health concern. Emerging evidence points towards metabolic inflammation as a key process in the fatty liver that contributes to multiorgan morbidity. Key extrahepatic comorbidities that … Continue reading
Posted in News
Comments Off on Metabolic inflammation – a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)?
Predicting response to rifaximin in irritable bowel syndrome with diarrhea: Is the answer blowing in the wind?
Irritable bowel syndrome (IBS) is one of the most common functional bowel disorder worldwide (Clin Gastroenterol Hepatol 2012;10:712-721). The diagnosis is based on a patient reporting a specific combination of symptoms, as defined by the Rome criteria… Continue reading
Posted in News
Comments Off on Predicting response to rifaximin in irritable bowel syndrome with diarrhea: Is the answer blowing in the wind?